利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.012 秒)

    Adamantane compounds
    2.
    发明授权
    Adamantane compounds 失效
    ADAMANTANE化合物

    公开(公告)号：US3668220A

    公开(公告)日：1972-06-06

    申请号：US3668220D

    申请日：1970-04-27

    申请人： LILLY CO ELI

    发明人： SZINAI STEPHEN S ,  LUNN WILLIAM H W

    IPC分类号： C07C53/138 ,  C07C53/44 ,  C07C55/30 ,  C07C59/11 ,  C07D209/58 ,  C07D307/77 ,  C07D27/28

    CPC分类号： C07D209/58 ,  C07C53/138 ,  C07C53/44 ,  C07C55/30 ,  C07C59/11 ,  C07D307/77

    摘要： WHEREIN EACH G independently represents hydrogen or straightchain alkyl of from one to six, both inclusive, carbon atoms; G'' represents hydrogen or acetyl; R represents hydrogen or alkyl of from one to six, both inclusive, carbon atoms; R'' represents halo, alkoxy containing from one to six both inclusive, carbon atoms in the alkyl group, hydrogen or alkyl of from one to six, both inclusive, carbon atoms; each R'''' independently represents hydrogen or alkyl of from one to six, both inclusive, carbon atoms; each R'''''' independently represents hydrogen or alkyl of from one to six, both inclusive, carbon atoms or both R'''''' groups taken together represent oxo(-0); X represents halo; and each n independently represents an integer of from zero to one, both inclusive. The terms ''''halo'''' and ''''halide'''' are employed herein to designate occurrences of bromine, chlorine and iodine. The adamantane compounds of formula VII AND VIII are useful as agents to achieve a depressant action on the central nervous system of warm blooded animals. The adamantane compounds of formulas I, II, III, IV, V and VI are useful as intermediates in the synthesis of the compounds of formulas VII and VIII.

    The present invention is directed to adamantane compounds of the formula:

    摘要翻译： 本发明涉及下式的金刚烷化合物：其中每个G独立地表示氢或1-6个碳原子的直链烷基; G'表示氢或乙酰基; R表示氢或1-6个碳原子的烷基， R'表示卤素，含有一至六个或两个以上的烷氧基，烷基中的碳原子，氢或一至六个碳原子的烷基，包括两个碳原子; 每个R“独立地代表氢或一至六个碳原子的烷基; 每个R“独立地表示氢或一至六个，包括两端的碳原子的烷基或两个R”基团一起代表氧代（-O）; X表示卤素; 并且每个n独立地表示0至1的整数。 术语“卤素”和“卤化物”在本文中用于指定溴，氯和碘的出现。

    Spiro-imide derivatives
    3.
    发明授权
    Spiro-imide derivatives 失效
    螺酰亚胺衍生物

    公开(公告)号：US4471124A

    公开(公告)日：1984-09-11

    申请号：US564599

    申请日：1983-12-22

    申请人： John L. Belletire ,  Reinhard Sarges

    发明人： John L. Belletire ,  Reinhard Sarges

    IPC分类号： C07C55/30 ,  C07D209/96 ,  C07D221/20 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D495/10 ,  C07D491/107 ,  C07D491/20 ,  C07D495/20

    CPC分类号： C07D221/20 ,  C07C255/00 ,  C07C55/30 ,  C07D209/96 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D495/10

    摘要： A series of spiro-imide compounds and their base salts with pharmacologically acceptable cations are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. Preferred member compounds include 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidone]-2', 5'-dione, 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-piperidine]-2', 6'-dione, 6-chloro-2,3-dihydro-spiro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione and 6,7-dihydro-spiro-[5H-benzo(b)thiophene-4,3'-pyrrolidine]-2',5'-dione. Methods for preparing these compounds from known starting materials are provided.

    摘要翻译： 公开了一系列螺酰亚胺化合物及其与药理学上可接受的阳离子的碱盐。 这些特定化合物可用于治疗某些慢性糖尿病并发症的药物。 优选的成员化合物包括2,3-二氢螺 - [1H-茚-1,3'-吡咯烷酮] -2 + 40,5'-二酮，2,3-二氢螺 - [1H-茚-2,3 ' - 吡咯烷] -2'，5'-二酮，3,4-二氢螺 - [2H-萘-1,3'-吡咯烷] -2'，5'-二酮，3,4-二氢 - 螺 - [2H-萘-1,3'-哌啶] -2'，6'-二酮，6-氯-2,3-二氢螺 - [4H-1-苯并吡喃-4,3'-吡咯烷] -2' ，5'-二酮和6,7-二氢 - 螺 - [5H-苯并（b）噻吩-4,3'-吡咯烷] -2'，5'-二酮。 提供了从已知原料制备这些化合物的方法。

    Imide derivatives
    4.
    发明授权
    Imide derivatives 失效
    酰亚胺衍生物

    公开(公告)号：US4442114A

    公开(公告)日：1984-04-10

    申请号：US458700

    申请日：1983-01-17

    申请人： John L. Belletire ,  Reinhard Sarges

    发明人： John L. Belletire ,  Reinhard Sarges

    IPC分类号： C07C55/30 ,  C07D209/96 ,  C07D221/20 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D495/10 ,  C07D211/88 ,  A61K31/445

    CPC分类号： C07D221/20 ,  C07C255/00 ,  C07C55/30 ,  C07D209/96 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D495/10 ,  Y10S514/866

    摘要： A series of spiro-imide compounds and their base salts with pharmacologically acceptable cations are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. Preferred member compounds include 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidone]-2',5'-dione, 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-piperidine]-2',6'-dione, 6-chloro-2,3-dihydro-spiro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione and 6,7-dihydro-spiro-[5H-benzo(b)thiophene-4,3'-pyrrolidine]-2',5'-dione. Methods for preparing these compounds from known starting materials are provided.

    摘要翻译： 公开了一系列螺酰亚胺化合物及其与药理学上可接受的阳离子的碱盐。 这些特定化合物可用于治疗某些慢性糖尿病并发症的药物。 优选的成员化合物包括2,3-二氢螺 - [1H-茚-1,3'-吡咯烷酮] -2'，5'-二酮，2,3-二氢螺 - [1H-茚-2,3' - 吡咯烷] -2'，5'-二酮，3,4-二氢螺 - [2H-萘-1,3'-吡咯烷] -2'，5'-二酮，3,4-二氢螺 - 2H-萘-1,3'-哌啶] -2'，6'-二酮，6-氯-2,3-二氢 - 螺 - [4H-1-苯并吡喃-4,3'-吡咯烷] -2' 5'-二酮和6,7-二氢 - 螺 - [5H-苯并（b）噻吩-4,3'-吡咯烷] -2'，5'-二酮。 提供了从已知原料制备这些化合物的方法。

    Method for lowering sorbitol levels using spiro-imides
    8.
    发明授权
    Method for lowering sorbitol levels using spiro-imides 失效
    使用螺酰亚胺降低山梨醇水平的方法

    公开(公告)号：US4307108A

    公开(公告)日：1981-12-22

    申请号：US106577

    申请日：1979-12-26

    申请人： John L. Belletire ,  Reinhard Sarges

    发明人： John L. Belletire ,  Reinhard Sarges

    IPC分类号： C07C55/30 ,  C07D209/96 ,  C07D221/20 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D491/107 ,  C07D495/10 ,  A61K31/40 ,  C07D209/54

    CPC分类号： C07D221/20 ,  C07C255/00 ,  C07C55/30 ,  C07D209/96 ,  C07D311/58 ,  C07D333/54 ,  C07D491/10 ,  C07D495/10

    摘要： A series of spiro-imide compounds and their base salts with pharmacologically acceptable cations are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. Preferred member compounds include 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidone]-2',5'-dione, 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-piperidine]-2',6'-dione, 6-chloro-2,3-dihydro-spiro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione and 6,7-dihydro-spiro-[5H-benzo(b)thiophene-4,3'-pyrrolidine]-2',5'-dione. Methods for preparing these compounds from known starting materials are provided.

    摘要翻译： 公开了一系列螺酰亚胺化合物及其与药理学上可接受的阳离子的碱盐。 这些特定化合物可用于治疗某些慢性糖尿病并发症的药物。 优选的成员化合物包括2,3-二氢螺 - [1H-茚-1,3'-吡咯烷酮] -2'，5'-二酮，2,3-二氢螺 - [1H-茚-2,3' - 吡咯烷] -2'，5'-二酮，3,4-二氢螺 - [2H-萘-1,3'-吡咯烷] -2'，5'-二酮，3,4-二氢螺 - 2H-萘-1,3'-哌啶] -2'，6'-二酮，6-氯-2,3-二氢 - 螺 - [4H-1-苯并吡喃-4,3'-吡咯烷] -2' 5'-二酮和6,7-二氢 - 螺 - [5H-苯并（b）噻吩-4,3'-吡咯烷] -2'，5'-二酮。 提供了从已知原料制备这些化合物的方法。